5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation,
and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and
bevacizumab. Fluorouracil (FU) has proven to be an effective and safe regimen in the
treatment of stage II and III rectal cancer. Recent evidence has proven
fluorouracil/leucovorin (FL) in combination with bevacizumab is superior to FL alone and when
combined with irinotecan is superior to (irinotecan plus fluorouracil/leucovorin (IFL) alone.
This trial will be one of the first clinical trials to evaluate a combination of targeted
therapy, radiation, and chemotherapy in the adjuvant treatment of a common solid tumor.